期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

膀胱肿瘤RASSF2A及NORE1A启动子甲基化状况研究 被引量：2

Hypermethylation of Promoter Region of RASSF2A and NORE1A in Bladder Carcinoma
下载PDF
导出
摘要 目的研究膀胱癌中,RASSF2A、NORE1A基因启动子甲基化状态在肿瘤发生发展中的作用。方法采用甲基化特异性PCR(methylation specific PCR,MSP)技术检测54例膀胱癌组织及其相应癌周正常组织RASSF2A、NORE1A基因启动子甲基化状态。结果(1)RASSF2A检出率仅为2/54,NORE1A仅为0/54;(2)相应癌周正常组织和3例正常膀胱组织均未发现该基因高甲基化改变;(3)甲基化状态与膀胱癌临床病理参数无明显相关性。结论RASSF2A、NORE1A在膀胱肿瘤中的甲基化率较低,并不适合进行临床筛查。 Objective To investigate the methylation bladder carcinoma and its role in tumorigenesis. Methods status of the promoter region of RASSF2A and NORE1A in The methylation status of promoter regions of RASSF2A and NORE1A was examined by MSP in 54 bladder carcinoma tissues and adjacent normal tissues from 54 cases. Results （ 1 ） 2/54 of bladder carcinoma tissues showed RASSF2A hypermethylation, and NORE1A showed 0/54. （2） None of paired adjacent normal tissues and three normal bladder tissues showed RASSF2A and NORE1A hypermethylation. （3） There was no significant correlation between the methylation status with the clinical pathological parameters in bladder carcinoma. Conclusion Hypermethylation rates of RASSF2A and NORE1A in bladder carcinoma are low, which suggest it is unsuitable for clinical screening.
作者 王楠楠 李智 于永春 段建敏
机构地区 同济大学附属第十人民医院检验科 兰州大学第二附属医院泌尿外科
出处 《同济大学学报（医学版）》 CAS 2006年第5期34-36,共3页 Journal of Tongji University(Medical Science)
关键词 RASSF2A NORE1A 膀胱肿瘤 甲基特异性PCR RASSF2A NORE1A bladder carcinoma MSP
分类号 R737 [医药卫生—肿瘤]
  • 相关文献

参考文献11

  • 1张剑英,李智.RASSF1基因与肿瘤的关系[J].国外医学（临床生物化学与检验学分册）,2005,26(2):120-122. 被引量：7
  • 2Agathanggelou A,Cooper WN,Latif F.Role of the Ras-association domain family 1 tumor suppressor gene in human cancers[J].Cancer Res,2005,65(9):3497-3508.
  • 3Hesson LB,Wilson R,Morton D,et al.CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations[J].Oncogene,2005,24(24):3987-3994.
  • 4Hesson L,Bieche I,Krex D,et al.Frequent epigenetic inactivation of RASSF1A and BLU genes located within the critical 3p21.3 region in gliomas[J].Oncogene,2004,23:2408-2419.
  • 5Aoyama Y,Avruch J.Norel inhibits tumor cell growth independent of Ras or the MST1/2 kinases[J].Oncogene,2004,23:3426-3433.
  • 6Vos MD,Martinez A,Ellis CA,et al.The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung[J].J Biol Chem,2003,278:21938-21943.
  • 7Vos MD,Ellis CA,Elam C,et al.RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor[J].J Biol Chem,2003,278:28045-28051.
  • 8Sakamoto-Hojo ET,Mello SS,Pereira E,et al.Geneexpression profiles in human cells submitted to genotoxic stress[J].Mutat Res,2003,544:403-413.
  • 9Irimia M,Fraga MF,Sanchez-Cespedes M,et al.CpG island promoter hypermethylation of the Raseffector gene NORE1A occurs in the context of a wild-type K-ras in lung cancer[J].Oncogene,2004,23:8695-8699.
  • 10Vos MD.The t (1;3) breakpoint-spanning involved in clear cell renal cell genes LSAMP and NORE1 are carcinomas[J].Cancer Cell,2003,4:405-413.

二级参考文献15

  • 1Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 2000, 25(3): 315-319.
  • 2Ortiz-Vega S, Khokhlatchev A, Nedwidek M, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene, 2002, 21(9): 1381-1390.
  • 3Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA, 2001, 98(13): 7504-7509.
  • 4Shivakumar L, Minna J, Sakamaki T, et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol, 2002, 22(12): 4309-4318.
  • 5Tomizawa Y, Kohno T, Kondo H, et al. Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res, 2002, 8(7): 2362-2368.
  • 6Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene, 2001, 20(12): 1509-1518.
  • 7Zhang YJ, Ahsan H, Chen Y, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog, 2002, 35(2): 85-92.
  • 8Byun DS, Lee MG, Chae KS, et al. Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma. Cancer Res, 2001, 61(19): 7034-7038.
  • 9van-Engeland M, Roemen GM, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene, 2002, 21(23): 3792-3795.
  • 10Dammann R, Schagdarsurengin U, Liu L, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene, 2003, 22(24): 3806-3812.

共引文献6

同被引文献1

引证文献2

二级引证文献3

同济大学学报（医学版）
2006年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部